{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"Adverse events will be graded by the CTCAE (Common Terminology Criteria for Adverse Events) 4.0 and summarized according to the worst grade observed since the first treatment dose.","groups":[{"description":"400 mg BID for 12 Days","id":"OG000","title":"Cohort 1"},{"description":"Defactinib 400 mg BID for 35 Days","id":"OG001","title":"Cohort 2"},{"description":"Defactinib 400 mg BID for 21 Days","id":"OG002","title":"Cohort 3"},{"description":"Defactinib 100 mg BID for 21 Days","id":"OG003","title":"Cohort 4"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients with at least one treatment-related treatment-emergent adverse events","reportingStatus":"POSTED","timeFrame":"Cohort 1, 40 days; Cohort 2, 42 days; Cohort 3, 28 days; Cohort 4, 28 days.","title":"Number of Patients With at Least One Adverse Event","type":"SECONDARY","unitOfMeasure":"Participants"}